Physician profile
Christopher R Cox
NPI 1649216276
$6,421.35
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $1,317 · 2021: $1,277 · 2022: $1,556 · 2023: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $837.14 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $813.56 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $612.98 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $435.25 | 2019-2023 | Farxiga |
| Abbvie INC. | $432.43 | 2021-2023 | Vraylar, Ubrelvy |
| Amarin Pharma, INC. | $359.61 | 2019-2022 | |
| Pfizer INC. | $349.30 | 2019-2023 | |
| Lilly USA, LLC | $282.63 | 2019-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $242.23 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $235.30 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $214.17 | 2019-2022 | |
| Amgen INC. | $201.78 | 2019-2023 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $167.82 | 2020-2023 | Airduo Digihaler |
| Otsuka America Pharmaceutical, INC. | $152.01 | 2022-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $139.81 | 2020-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $135.78 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.19 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $109.04 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $102.30 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.05 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.35 | 2022 | |
| Esperion Therapeutics, INC. | $52.02 | 2021 | |
| Allergan, INC. | $50.34 | 2019-2020 | |
| Medtronic, INC. | $46.16 | 2021-2023 | Corevalve Evolut R, Mvp |
| Zyla Life Sciences, INC. | $39.63 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $32.20 | 2020-2021 | |
| Genentech USA, INC. | $21.85 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.52 | 2022 | |
| Medtronic Vascular, INC. | $15.52 | 2020 | |
| Phadia US INC. | $14.87 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.83 | 2023 | Gvoke Hypopen |
| Tris Pharma INC | $13.82 | 2023 | Dyanavel Xr |
| Antares Pharma, INC. | $12.86 | 2023 | Tlando, Nocdurna, Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.